transplant rejection
CareDx Receives CE Mark for Hematopoietic Cell Transplantation Testing Kit, Analysis Software
The designation furthers the firm's expansion into the stem cell transplant space, which began with the launch of AlloCell in 2020.
CareDx Q1 Revenues up 18 Percent
The firm said March was its highest ever month of testing volume for its heart and kidney transplant testing services.
Three new studies focusing on the heart, lungs, and kidneys add to a growing body of evidence in support of donor-derived cell-free DNA as an organ health measure.
Thermo Fisher Scientific Deal Expands Possibilities for Exosome Dx Business, Bio-Techne CEO Says
Premium
The deal with Thermo Fisher is for the development of Bio-Techne's second test in its Exosome Diagnostics portfolio, a multigene assay for kidney transplant rejection.
Bio-Techne, Thermo Fisher Scientific to Further Develop, Commercialize Kidney Transplant Rejection Assay
The exosome-based, liquid biopsy assay discriminates between T-cell mediated rejection and antibody mediated rejection to help improve patient outcomes.
Oct 29, 2021
May 6, 2021
Natera Q1 Revenues Grow 62 Percent
May 5, 2021
CareDx Q1 Revenues up 76 Percent
Mar 19, 2021
Mar 16, 2021
NephroSant Raises $16M in Series A Funding Round
Feb 25, 2021
Feb 24, 2021
CareDx Q4 Revenues Up 64 Percent
Jan 27, 2021